Morgan Stanley assumed coverage of Regenxbio (RGNX) with an Overweight rating and $22 price target The firm appreciates the attractiveness of gene therapy in concept for VEGF-mediated diseases given the unmet need, but cautions that subretinal delivery may limit commercial uptake and suprachoroidal delivery data presented to date is still early. The analyst says the first functional results for RGX-202 in Duchenne muscular dystrophy will be shared in a company webcast on Monday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: